MORRISVILLE, N.C., Nov. 20, 2025 /PRNewswire/ -- Revian, a leader in light therapy for hair regrowth, today announced it has secured up to $13 million, in gross proceeds, in financing led by Flashpoint, an international tech investment firm with approximately $600 million AUM focused on global tech companies. The mix of equity and growth debt funding will support Revian's commercial scale-up, product expansion, and launch of international operations.

Revian's FDA cleared at-home device utilizes patented dual-wavelength red light technology to stimulate nitric oxide production, which (1) inhibits 5-alpha reductase thereby reducing dihydrotestosterone (DHT) levels; (2) enhances scalp microcirculation and (3) reduces scalp inflammation. As a result, Revian's device addresses three well-established biological drivers of hair follicle miniaturization and progressive hair loss. This multi-targeted mechanism positions Revian as a clinically meaningful adjunct and, in select cases, a non-pharmacologic alternative to conventional therapies.

"We've gained tremendous conviction in Revian through the depth of their scientific documentation and the rigor of their clinical trials, as well as their cutting-edge digital technology, which clearly set them apart in the market," said Denis Mosolov, Managing Partner at Flashpoint Growth Debt. "Meeting and collaborating with the leadership team has only reinforced our confidence in John's ability to bring the vision for Revian to life, and we're genuinely excited to be part of this journey."

"This financing enables us to meet accelerating demand from medical practices nationwide while laying the foundation for our global expansion," said John Oakley, Chief Executive Officer of Revian. "We've demonstrated strong clinical results and a scalable physician-led model. Flashpoint's partnership allows us to extend that success to new markets and patients worldwide."

Revian's RED device has an app-integrated platform which enables physicians to monitor patient compliance in real time, an important differentiator in optimizing long-term treatment success and driving clinical accountability.

Tungsten Advisors acted as the sole placement agent for the offering.

‍